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It’s not true that things have never been this bad before.
They were about the same in the early 1970s. But it is true
that they have never been worse. When a scientist doing
work in genomics, or cell biology, or biochemistry, or
immunology submits a grant proposal to the US National
Institutes of Health (NIH), the largest supporter of life
science research in the world, his or her chance of it being
funded are at historic lows. And this situation is threatening
to destroy the jewel in the crown of US science, the system of
competitive peer review of research applications. 
In contrast to the hierarchical system in many other coun-
tries, where research funds are often distributed to heads of
departments or centers, who then dole them out to their
component research groups, in the United States most uni-
versity research faculty are independent entrepreneurs,
who compete with one another for funding on the basis of
the quality of their proposals. The competition is judged by
the applicant’s peers - scientists in the same general area of
research. This Darwinian selection system has, for over half
a century, largely guaranteed that merit, not cronyism,
determines what science is supported by the federal govern-
ment. The procedure is straightforward, and until now has
worked remarkably well. 
But I think the procedure has stopped working well because
of the perception that financial support for science in the US
is drying up. Thanks to the war in Iraq and tax cuts mostly
for the richest Americans, federal funding for life science
research, which doubled over a seven year period not long
ago, has remained flat in real dollars and declined in
inflation-adjusted dollars during the last few years. To make
matters worse, scientists from all disciplines flocked to the
NIH for support like pigs to a trough during the budget-
doubling period, resulting in a huge increase in the number
of submitted research proposals. And NIH administrators
didn’t help matters either. They seem to have assumed that
the big increases in their budget would go on forever, and
rather than engineer a soft landing for when the inevitable
crash came, they spent like sailors on shore leave, mostly for
big new programs that benefited only a small number of
investigators (Hello, Structural Genomics Initiative). And
since new programs are like living creatures and fight for
survival with the ferocity of a cornered wolverine, the chance
that we could rid ourselves of these white elephants when
budgets got tight has, of course, turned out to be zero. 
With chance for support dwindling, individual investiga-
tors, the lifeblood of creative scientific research, are begin-
ning to flee the field. I personally know of many young
research students who are either going into industry or
leaving science altogether because they believe that they
have little possibility of being able to obtain funding were
they to set up their own laboratory. And I know of an equal
number of senior scientists who are going into administra-
tion or taking early retirement, not because they want to, but
because they have become discouraged about the prospects
for continued support. 
The Bush administration and our own greed are to blame for
this situation, but the immediate cause of the problem from
the perspective of the individual investigator is what I see as
a breakdown of the peer-review system. Unless that can be
fixed, the likelihood of a turnaround, even if budget levels
improve, is not good. 
Peer review of applications submitted to NIH takes place in
two steps. Applications for support from the NIH are evalu-
ated initially by peer-review groups of scientists who are
assigned grants to review on the basis of their expertise. The
objective of this initial peer review is to determine the scien-
tific and technical merit of the proposed research project. If
the project represents a continuation of one funded previ-
ously, the productivity during that period is also considered
in evaluating the competing renewal. The panels that review
the proposals are called Scientific Review Groups and are
managed by Scientific Review Administrators, employees of
the Center for Scientific Review, one of the approximately 27institutes and centers that are the components of the NIH.
Approximately half of the proposals considered at a particu-
lar Scientific Review Group meeting will be triaged as being
not competitive for funding at all. The top half are discussed
in detail and are assigned priority scores: numerical ratings
of scientific merit from 100 (best) to 500 (worst). The
scores are converted into percentile rankings that indicate,
for example, whether a grant is in the top 20% of all grants
scored by that group (the 20th percentile). After the conclu-
sion of the meeting, the Scientific Review Administrator
prepares a summary statement for each discussed proposal
that includes the reviewers’ written comments, recommen-
dations of the group and the priority score and percentile
ranking. The summary statement is sent to the program
staff of the awarding institute and to the applicant. (The
second level of peer review is carried out by the NIH
National Advisory Councils. These councils are composed of
scientists from the extramural research community and
public representatives. They are meant to ensure that the
NIH receives advice from a cross-section of the US popula-
tion in the process of its deliberation and decisions. Coun-
cils don’t usually overturn the funding decisions of the
Science Review Groups, but they do have that power.) 
There is some confusion about the meaning of the per-
centile score awarded by Science Review Groups as com-
pared with the success rate for a grant being funded. The
success rate is the total number of grant applications that
are funded in a given fiscal year divided by the number of
grant applications that were peer-reviewed. The percentile
is a ranking that shows the relative position of each applica-
tion’s priority score among all scores assigned by that par-
ticular Scientific Review Group at its last three meetings.
For a given NIH Institute, the success rate usually differs
from the percentile ranks. The percentile ranks are calcu-
lated using all applications reviewed by that initial Review
Group, which includes applications assigned to other NIH
institutes and centers. If grants assigned to one institute
tend to receive better priority scores than the NIH average,
then that year more than, say, 10 percent of its grant appli-
cations will rank better than the 10th percentile. Applica-
tions that are amended and resubmitted during the same
fiscal year are also only counted once in the success-rate
calculations, whereas all applications, both original and
amended versions, are included when the percentiles are
calculated. Therefore, funding all applications with ranks
better than, say, the 20th percentile will result in a success
rate greater than 20 percent when revised versions of some
projects are removed from the success-rate base. 
For 2006 the percentile cut-off for a grant to be funded by
the National Institute of Allergy and Infectious Diseases is
the 14th percentile. It’s the 10.5th percentile in the National
Institute of Aging, the 11th percentile for the National
Cancer Institute, and the 12th percentile for the National
Institute of Neurologic Diseases and Stroke. These translate
into success rates in the order of slightly above 20% for
most institutes, which can be compared with success rates
close to 40% 7-10 years ago. (Most institutes try to give
young investigators a break by setting the ‘payline’ about 2-
5 percentile points higher for their proposals, resulting in a
slightly higher success rate for first-timers.) 
A drop in success rate of 50% is nothing to be happy about.
But the number that really matters for peer reviewers is the
percentile ranking, because this is what the Scientific
Review Group members are aware of when they review a
proposal. If they know that the payline is around the 10th
percentile, as it is now, then they also know that out of 100
proposals that might be reviewed at that meeting, only
about 10 will get funded. And that knowledge is the
problem. 
Ten years ago, when grants scoring better than the 25th or
sometimes even the 30th percentile were being funded,
reviewers knew that most good proposals would be supported,
and that if they made a mistake about a grant at the margin,
they were not making a mistake about the very best science.
Consequently, the tone in review-group discussions was
that of constructive criticism. Reviewers tried hard to find
reasons to support work, particularly by young investiga-
tors, and their comments were often encouraging and
guiding. No one was afraid that if someone else were
funded, it would hurt their own chances of being funded;
the pie was large enough that everyone felt they had a fair
chance at a slice. 
Not any more. When the percentile cut-off is around 10%,
reviewers are being asked to do the impossible. They have
to make choices from among research proposals that they
themselves have evaluated as being better than 90% of all
other grants in the field. No human being can make objec-
tive distinctions between grants at that level of quality.
Because, since they must, subjectivity inevitably creeps in.
Now Scientific Review Group members must try to find
reasons not to fund proposals. The tone of reviewing is one
of nit-picking. Increasingly silly criteria are being used to
distinguish between applications: one of my proposals lost
points because I did not give enough detail about how I was
planning to carry out a particular experimental technique.
Forgive me if I was a trifle starry-eyed about it, but I really
didn’t think I needed to demonstrate my competence in
using a method that I had invented some fifteen years
before. 
Of course, when funds are this tight, generosity of spirit is in
danger of being replaced by unenlightened self-interest.
Every funded proposal now is a direct threat to one’s own
grants being funded. This mentality inevitably leads to turf
protection, as reviewers in a subfield look after one another’s
applications, even if these are not of the best quality. To the
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Genome Biology 2006, 7:105credit of most reviewers, I haven’t seen too much of this, but
I’ve sure seen more than I saw a few years ago.  
And if good grants are not funded simply because they just
miss the cut-off, for whatever reason, including pure bad
luck, it’s not likely that there are many, if any, substantive
criticisms that the investigators can address in a resubmis-
sion. Imagine how discouraging it must be to write a good
proposal and see it not funded, and not to have any idea how
to improve it because there’s really nothing to improve. Who
wants to roll the dice again with those odds?
But I think it’s equally discouraging for the reviewers. If
you’re given 20 proposals to evaluate out of a crop of, say,
100, and you determine that 6 are of excellent quality, but
you know that the probability that more than 2 of these will
actually get funded is nil, how can you feel good about what
you’re doing? Or about your own prospects for getting
funded? Or about the future of your profession? Also, with a
payline this low there’s a significant chance that nothing you
review will get funded, making the whole, time-consuming
exercise one of futility. Good people won’t serve on study
sections under these circumstances.
When the payline hovers around the 10th percentile, when
fewer than a quarter of submitted grants are funded, and
when the process of peer review has become one of trying to
make judgments among things of equal quality, the system is
broken. But I don’t think it’s broken beyond repair, at least
not yet. Next month, I’ll tell you how I think it can be fixed.
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